Karyopharm Therapeutics Inc.
KPTIQ- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001503802
In the last 90 days, Karyopharm Therapeutics Inc. insiders filed 0 open-market purchases and 3 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Other share classesKPTI
Key figures
- Market capCalculated value looks implausible
- –
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $2.14K in total
- 3
- 13F holdersQ2 2026
- 0
- 13F valueReported value at the end of Q2 2026
- $0
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $146.1M
- +0.6% year over year
- Net income, FY2025
- -$196.0M
- No comparable prior period
- Free cash flow, FY2025
- -$75.4M
- No comparable prior period
- Revenue, Q2 FY2026
- $33.4M
- −11.9% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $196.0M (134.2% of revenue).
Superinvestors holding KPTIQ, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding KPTIQ at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Karyopharm Therapeutics Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 19, 2026 (view filing)4:03 PM ET | Oct 16 | 3 days | Abate KristinChief Accounting Officer | SSale | −4.79K | $0.344 | −$1.65K | −20.5%18.6K after | |
| Oct 2, 2026 (view filing)4:01 PM ET | Oct 1 | 1 day | Abate KristinChief Accounting Officer | SSale | −378 | $1.19 | −$449.82 | −1.6%23.4K after | |
| Sep 2, 2026 (view filing)4:57 PM ET | Sep 1 | 1 day | Abate KristinChief Accounting Officer | SSale | −19 | $2.02 | −$38.38 | −0.1%23.8K after | |
| Jul 30, 2026 (view filing)4:42 PM ET | Jul 28 | 2 days | Poulton StuartEVP, Chief Development Officer | SSale | −189 | $7.10 | −$1.34K | −0.2%94.6K after | |
| May 15, 2026 (view filing) | May 14 | 1 day | Poulton StuartEVP, Chief Development Officer | SSale | −403 | $9.50 | −$3.83K | −0.4%94.8K after | |
| May 15, 2026 (view filing) | May 14 | 1 day | Rangwala ReshmaEVP & Chief Medical Officer | SSale | −408 | $9.50 | −$3.88K | −0.7%56.8K after | |
| May 15, 2026 (view filing) | May 14 | 1 day | Cheng Sohanya RoshanEVP & Chief Commercial Officer | SSale | −324 | $9.50 | −$3.08K | −0.3%107.9K after | |
| May 15, 2026 (view filing) | May 14 | 1 day | Abate KristinChief Accounting Officer | SSale | −53 | $9.50 | −$503.5 | −0.2%23.8K after | |
| May 15, 2026 (view filing) | May 14 | 1 day | Paulson Richard A.President and CEO | SSale | −2.20K | $9.50 | −$20.9K | −0.8%269.7K after | |
| May 15, 2026 (view filing) | May 14 | 1 day | Mano MichaelEVP, CLO&Secretary | SSale | −266 | $9.50 | −$2.53K | −0.3%94.4K after |
Top 10 13F holders, Q2 2026
View all: Top 10 13F holders, Q2 2026The largest institutional positions in Karyopharm Therapeutics Inc. at the end of Q2 2026; share changes are against Q1 2026.
No institution reported holding KPTIQ in 13F filings for Q2 2026.
Politician trades
All politician trades in KPTIQ1 member of Congress reported 1 trade in Karyopharm Therapeutics Inc. since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Mar 22, 2025 |  Ashley Moody Senate · FL | Sell (full) | $1K-$15K |
Senate · FL · Mar 22, 2025
Sell (full)$1K-$15K